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Alternative Splicing Coupled Nonsense-Mediated Decay
Generates Neuronal Cell Type-Specific Expression of SLM
Proteins
Lisa Traunmu¨ller, Caroline Bornmann, and XPeter Scheiffele
Biozentrum, University of Basel, 4056 Basel, Switzerland
The unique physiological andmorphological properties of neuronal populations are crucial for the appropriate functioning of neuronal
circuits. Alternative splicing represents an attractive mechanism for generating cell type-specific molecular repertoires that steer neu-
ronal development and function. However, the mechanisms that link neuronal identity to alternative splicing programs are poorly
understood.We report that cell type-specific,mutually exclusive expressionof twoalternative splicing regulators, SLM1andSLM2, in the
mouse hippocampus is achieved by a cross-repression mechanism. Deletion of SLM2 in vivomodifies alternative splicing of its paralog
Slm1 and stabilizes its mRNA, resulting in expression of SLM1 in previously SLM2-expressing cells. Despite this ectopic upregulation of
SLM1, loss of SLM2 severely disrupts the alternative splicing regulation of Nrxn1, Nrxn2, and Nrxn3, highlighting that the two SLM
paralogs have partially divergent functions. Our study uncovers a hierarchical, SLM2-dependent mechanism for establishing cell type-
specific expression of neuronal splicing regulators in vivo.
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Introduction
The mammalian nervous system consists of a complex network
of neuronal cell types, which are defined by unique molecular,
physiological, and anatomical properties. Cell type-specific prop-
erties rely on gene expression programs that shape protein levels
and isoform repertoires, including cell surface receptors, ion
channels, signaling, and transport regulators. The transcriptional
mechanisms that specify neuronal cell types and guide their
growth during early development have been extensively studied
(Dasen and Jessell, 2009; Hobert et al., 2010). By comparison,
there is a lack of knowledge about cell type-specific gene expres-
sion programs associated with neuronal connectivity and func-
tion, in particular with respect to the complex recognition events
between synaptic partners.
Significant diversification of protein function is achieved at
the level of alternative pre-mRNA splicing (Norris and Calarco,
2012; Darnell, 2013; Zheng and Black, 2013). Temporally and
spatially controlled alternative splicing programs can direct mo-
lecular and, thereby, functional diversity of gene products. More
recently, alternative splicing-dependent nonsense-mediated
mRNA decay (NMD) has emerged as a mechanism for control-
ling gene expression levels (McGlincy and Smith, 2008; Bicknell
et al., 2012). To this end, alternative splicing directs the incorpo-
ration of exons, which contain premature translation termina-
tion codons, leading to the targeted degradation of the mRNA.
Thus, alternative splicing not only contributes to the molecular
diversification of gene products but also plays a major role in the
regulation of levels and kinetics of protein expression.
A prerequisite for cell type-specific gene regulation through
alternative splicing is the selective expression of alternative splic-
ing regulators in defined cell populations. One interesting exam-
ple are the KH-domain containing RNA-binding proteins
Sam68, SLM1, and SLM2 (Sam68-like mammalian proteins),
which belong to the STAR (signal transduction and activator of
RNA) family. SAM68 (Src-associated substrate in mitosis of 68
kDa) is ubiquitously expressed in neuronal and non-neuronal
cells, whereas SLM1 and SLM2 exhibit a remarkable, mutually
exclusive expression in neuronal cell types (Di Fruscio et al.,
1999; Venables et al., 1999; Stoss et al., 2004; Iijima et al., 2011,
2014). Notably, SLM1 and SLM2 are important regulators of
neuron-specific alternative splicing, as both proteins repress in-
corporation of alternative exons at the alternatively spliced seg-
ment 4 (AS4) inNrxn1,Nrxn2, andNrxn3, a class of synaptic cell
surface receptors (Iijima et al., 2011, 2014; Ehrmann et al., 2013).
The resulting NRX AS4 protein variants differ in their interac-
tions with cell surface ligands, and disruption of alternative splic-
ing at AS4 results in defects in synapse formation and plasticity
(Boucard et al., 2005; Chih et al., 2006; Graf et al., 2006; Aoto et
al., 2013). Despite this critical importance of SLM1 and SLM2
function in generating cell type-specific repertoires of NRX iso-
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forms, the mechanisms underlying the mutually exclusive ex-
pression of SLM1 and SLM2 proteins in the mammalian nervous
system are unknown.
In this work, we uncover that deletion of Slm2 in mice results
in an unexpected elevation of SLM1 expression, specifically in
cells formerly expressing SLM2. In wild-type but not Slm2KO
neurons, Slm1mRNA is targeted for NMD by use of a previously
uncharacterized splice donor site in the 3UTR. Ectopic expres-
sion of Slm2 in dentate granule cells of the hippocampus is suffi-
cient to suppress endogenous SLM1 expression. Surprisingly,
deletion of Slm2 alone results in a profound disruption in alter-
native splicing regulation of Nrxn1, Nrxn2, and Nrxn3, despite
the upregulation of Slm1. Our study highlights a key function for
Slm2 in neuronal alternative splicing regulation by directing cell
type-specific splice variant choices of Nrxns. Moreover, our re-
sults provide strong genetic evidence for alternative splicing cou-
pled NMD in instructing cell type-specific gene expression
patterns in vivo.
Materials andMethods
Knock-out mice. Slm1KO mice were previously described (Iijima et al.,
2014). An Slm2 conditional allele was generated by homologous recom-
bination in mouse embryonic stem cells. Briefly, a genomic DNA frag-
ment containing exon 2 (ENSMUSE00000328887)was flanked by a LoxP
site and a FRT-PGK-neo-LoxP cassette encoding neomycin phospho-
transferase under the control of the phosphoglycerate kinase 1 promoter.
The targeting vector was electroporated into 129SvEvTac embryonic
stem cells. Homologous recombination in G-418-resistant clones was
confirmed, and selected cells were blastocyst injected. Chimeric animals
were crossed with ROSA-26 Flpe mice (Farley et al., 2000) to remove
PGK-neo sequences through Frt/Flp-mediated excision. Slm2flox/mice
were crossed with CMVcre deleter mice (Schwenk et al., 1995) to create a
germline deletion of exon 2. The Slm2flox allelewas detected by PCRusing
primers 5-GCTTTACAGTAGAGAAACTGG-3 (Lox gtF), 5-
CATAGATGACCTGCTGTCAG-3 (Lox gtR), 5-CGGTTGGATGG-
TATACATGAC-3 (Frt gtF), and 5-CAATGCTGTTACTCATCAGG-3
(Frt gtR). Slm1:Slm2DKO mice were generated by intercrossing of the
individual mutant mice. The resulting homozygous mice were viable.
Antibodies. Polyclonal antibodies for SAM68, SLM1, and SLM2 were
previously described (Iijima et al., 2014). Commercially available anti-
bodies were used: mouse anti--tubulin (E7, DSHB, 1:10000), mouse
anti-GFP (Invitrogen, 1:1000), andmouse anti-NeuN (Millipore Biosci-
ence Research Reagents, 1:2000).
Molecular biology procedures. For immunoblotting, either HRP-
conjugated secondary antibodies and Pierce ECLWestern Blotting Sub-
strate or fluorescent IRDye coupled secondaries were used. Signals were
acquired using an image analyzer (Bio-Rad, ChemiDoc MP Imaging
System and Li-Cor, Odyssey). Dissociated cultures of mouse hippocam-
pal cells were prepared from P0 pups and maintained in Neurobasal
medium (Invitrogen ) containing 2%B27 (Invitrogen) supplement and 2
mM Glutamax (Invitrogen) at 37°C and 5% CO2. Cylcoheximide was
applied at a final concentration of 50 g/ml for 4 h before harvesting.
Total RNA from cultured cells was extracted with Trizol and purified
using QIAGEN RNeasy Mini Kit.
Alternative splicing analysis. PCR primer sequences are as follows:
Nrxn1 AS4, 5-TGTTGGGACAGATGACATCGCC-3 and 5-
GAGAGCTGGCCCTGGAAGGG-3; Nrxn2 AS4, 5GTGCGCTT-
TACTCGAAGTGGTG3 and 5CCCATTGTAGTAGAGGCCGGAC3;
Nrxn3 AS4, 5TTGTGCGCTTCACCAGGAATG3 and 5AGAGCCCA-
GAGAGTTGACCTTG3; Gapdh, 5GCTTGTCATCAACGGGAAG3
and 5TTGTCATATTTCTCGTGGTTCA3; and Slm1 Ex8-Ex9b,
5CTACGGTCATGGAGTAAACGAG3 and 5 GGGAATACAA-
GAAATAGTGGGAGC3; and Slm1 Ex8-Ex10, 5CTACGGTCATG-
GAGTAAACGAG3 and 5CCCTTTAGGCCATCATATCTGC3.
Sequences of quantitative PCR primers. Quantitative PCR was per-
formed on a StepOnePlus qPCR system (Applied Biosystems). Gene ex-
pression assays were used with TaqMan Master Mix (Applied
Biosystems) or Power SYBRGreenMasterMix (AppliedBiosystems) and
comparative CT method. The cDNA levels were normalized to Gapdh
cDNA.
Commercially available gene expression assays for Gapdh
(Mm99999915g1), Nrxn1 (Mm00660298_m1), Nrxn2 (Mm01236851_
m1), andNrxn3 (Mm00553213_m1)were fromApplied Biosystems; and
assays for Slm1 (Mm.PT.58.41510930) and Slm2 (Mm.PT.58.10822025)
were from IntegratedDNATechnologies. Customgene expression assays
to interrogate Nrxn splicing at AS4 were previously described (Iijima et
al., 2014).
Primer sequences used with Power SYBR Green PCRMastermix were
as follows: Slm1 Ex3-Ex4, 5-GACCAAGAGGAAACTCCTTGAA-3 and
Figure 1. A, Targeting strategy for generation of conditional Slm2KO mice. The Khdrbs3 gene encoding SLM2 protein was modified by insertion of LoxP sites (blue) flanking exon 2 (E2) and
targeted ES cells isolated based on G418-resistance conferred by the PGKneo cassette (orange). PGKneowas subsequently excised by breeding to ROSA-26 Flpemice. The Slm2 knock-out allele was
generated by crossing Slm2 floxed animals with CMV cre deletemice.B, Successful ablation of SLM2was verified byWestern blot analysis of cortical and testis tissue. C, Western blot analysis of two
sets ofWTand Slm2KO littermates, testedwith twodifferent antibodies (A,B) against twodifferent epitopes of the SLM2protein. Slm2 encodes several protein variants detected as bands of different
electrophoretic mobility.
16756 • J. Neurosci., December 10, 2014 • 34(50):16755–16761 Traunmu¨ller et al. • Cross-Repression of Alternative Splicing Factors
5-GGCATGACTCATCCGTGAATA-3; Slm1 Ex8-9a, 5-GTGCCT-
GAATACTATGACTACGG-3 and 5-GAGACCACAGGCTATGAA
TTGT3; Slm1 Ex9a-9b, 5-CATCTGTGACCTCCTCAAAGAC-3 and
5-TGTCCACGTCACATTAACAGTAT-3; and Slm1 Ex9a-10, 5-
CATCTGTGACCTCCTCAAAGAC-3 and 5-CCCTTTAGGCCAT
CATATCTGC-3.
Immunohistochemistry, image acquisition, and statistical analysis. Ani-
mals (male and female) were transcardially perfused with fixative (4%
PFA/15% picric acid in 100 mM phosphate buffer, pH 7.2). Tissue was
sectioned at 50m in PBS on a vibratome (VT1000S, Leica), and floating
sections were immunostained following standard procedures. Images
were acquired at room temperature on an inverted LSM700 confocal
microscope (Zeiss) using 10 and 63Apochromat objectives and con-
trolled by Zen 2010 software. Images were assembled using Adobe Pho-
toshop and Illustrator software. For quantitative assessment of protein
upregulation or downregulation, ImageJ was used. Statistical analysis
was done with Prism software (GraphPad software). All statistical data
are mean  SEM. Data were tested for normality using ANOVA and
Bonferroni’s or Dunnett’s post hoc test for multiple comparisons.
All procedures related to animal experimentation were reviewed and
approved by the Kantonales Veterina¨ramt Basel-Stadt.
Adeno-associated virus (AAV) production. Viral supernatants were
produced by cotransfection of HEK293T cells with a mixture of three
plasmids. The plasmid mixture consisted of 70 g of AAV helper
plasmid (Rep/Cap, Serotype II), 200g of AAV pHGTI-adeno1 (Plas-
mid Factory), and 70 g of vector plasmid Synapsin-SLM2-2A-Venus
or Synapsin-EGFP (containing the human synapsin promoter). At
45–60 h after transfection, medium containing viral particles was
harvested and purified using the Iodixanol purification method. The
fraction samples were dialyzed and concentrated inMillipore Amicon
100K columns, washed 3 with PBS, and centrifuged at 3500 rpm at
4°C. Viruses were frozen in aliquots and stored at 80°C. Viruses
were delivered by stereotaxic injection at postnatal day 8 into the
dentate gyrus (DG) of the mouse hippocampus. Infected cells were
marked by EGFP expression from the same vector. Animals were
transcardially perfused at postnatal day 40, and 50-m-thick vi-
bratome slices were analyzed by immunohistochemistry.
Figure 2. A, Upregulation of SLM1 in different brain regions in Slm2KO mice (left). Quantification of SLM1/tubulin ratios in WT and Slm2KO mice of the hippocampus and cortex (right) (n 4
animals, 8 weeks old). **p 0.01. B, Quantitative RT-PCR for total Slm1 and Slm2mRNA of hippocampal tissue. WTmRNA/Gapdh values were set to 1.0 and compared with Slm2KO values (n 4
animals, 8 weeks old).
Figure 3. A, Hippocampal sections of WT, Slm2 KO, and Slm1 KO mice were stained for the neuronal marker NeuN, as well as for SLM1 and SLM2. Scale bar, 200m. B, Quantification of mean
intensities of SLM1 and SLM2 in DG, CA1, and CA3 areas for Slm1KO and Slm2KO animals (n 4 animals, 3months of age, 2 sections per animal were used). Relative values comparedwith NeuN are
plotted. ns, Not significant ( p	 0.05). *p 0.5. **p 0.01. ***p 0.001. These values are the raw fluorescent valueswithout background subtraction. The KO genotypes serve as an indication
of respective background labeling.
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Results
Ablation of Slm2 in vivo results in elevated expression
of Slm1
To explore functions of the RNA-binding protein SLM2 in vivo, a
novelmouse knock-out Slm2 allele was created inwhich exon2 of
the mouse Khdrbs3 gene (which encodes for SLM2) was flanked
by LoxP sites. Global Slm2KO mice were generated by cre-
mediated recombination in the germline. Removal of exon 2 in-
troduces multiple premature stop codons and disrupts the Slm2
open reading frame (Fig. 1A). SLM2 is mainly expressed in the
brain and in testis (Stoss et al., 2004; Venables et al., 2004); we
thus investigated loss of SLM2 in these body regions (Fig. 1B).
Additionally, Western blotting analysis with two SLM2-specific
antibodies directed against different epitopes further confirmed
that Slm2KO mice lacked detectable SLM2 protein expression
(Fig. 1C). Slm2KOmice were viable and fertile and did not exhibit
obvious behavioral abnormalities, as previously reported for a
different Slm2KO allele (Ehrmann et al., 2013).
Upregulation of SLM1 in previously SLM2-positive cells
Surprisingly, we detected a 2.5-fold upregulation of SLM1 pro-
tein levels in hippocampus and cortex of Slm2KOmice (Figure 2A;
one-way ANOVA with Bonferroni post hoc test, p  0.01). A
significant increase was also detected for Slm1mRNA in the hip-
pocampus of Slm2KO mice (Fig. 2B; one-way ANOVA with Bon-
ferroni post hoc test, p  0.01). By contrast, no alterations were
observed for the closely related RNA-binding protein SAM68
(data not shown). To explore whether SLM1 is globally elevated
or whether its upregulation is restricted to specific cell popula-
tions, we performed detailed immunohistochemical analysis us-
ing SLM1- and SLM2-specific antibodies. Principal cells in the
mature hippocampus exhibit a remarkable, cell type-specific
expression pattern of SLM1 and SLM2: SLM1 is expressed in
dentate granule cells, and a specific subgroup of inhibitory in-
terneurons, however, is absent from the cornus ammonis-1
(CA1) and CA3 pyramidal cells. By contrast, SLM2 is highly ex-
pressed in the CA1 and CA3 pyramidal cells and a different set of
interneurons, but not detectable in the DG (Stoss et al., 2004;
Iijima et al., 2014) (Fig. 3A, top). In Slm2KO mice, SLM1 was
significantly upregulated in CA1 and CA3, whereas expression
in DG was unchanged (Fig. 3A,B; two-way ANOVA with Bon-
ferroni post hoc test). Thus, in the absence of SLM2, formerly
SLM2-positive cells selectively turn on SLM1 expression. This
suggests that the mutually exclusive expression pattern of
SLM1 and SLM2 in neuronal populations might be achieved
through cross-repression of SLM1 by SLM2. Interestingly, we
did not detect an analogous upregulation of SLM2 in the DG
of Slm1KO mice (Fig. 3A,B). These findings suggest that SLM2
is required for spatially restricting SLM1 expression in a uni-
directional manner.
Slm2 is required and sufficient to establish the mutually
exclusive expression pattern of SLM proteins
Considering that SLM2 is an RNA-binding protein, we hypothe-
sized that it may suppress Slm1 expression by targeting Slm1
mRNA for NMD in wild-type animals. To test this possibility, we
Figure4. A, Quantitative RT-PCR for total Slm1 and Slm2mRNA.Mousehippocampal cultureswere treated at day in vitro7 for 4 h eitherwith the translation blocker cycloheximide (CHX) or DMSO
(n3 independentlygenerated cultures).WTmRNA/Gapdhvalues inDMSO-treated control cellswere set to1.0and comparedwith cells treatedwithCHX. There is a significantupregulationof Slm1
in theWTwhen treatedwith CHX; however, there is no upregulation of either Slm1 or Slm2 in the Slm2KO. ns, Not significant ( p	 0.05). ***p 0.001.B, Schematic representation of incorporation
of exon 10 and exon 11 and primer binding sites for quantitative RT-PCR. Chromosome coordinates are taken fromUSCS Genome Browser (release date reference GRCm38/mm10). All chromosome
coordinates startwith 3217. C, Quantitative RT-PCR for increases in Slm1 transcripts at various exons comparingWT and Slm2KO animals (n 4 animals, 8weeks old). ns, Not significant ( p	 0.05).
*p0.5. **p0.01. ***p0.001. For the quantitative RT-PCR, primer sets flanking fromexon9aonwards insteadof exon8were usedbecause of the sizes of the exons.D, Exon spanningRT-PCR
of WT and Slm2 KO animals. E, The transcript targeted for NMD (Ex8–10) is stabilized in wild-type animals when treated with CHX.
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treated cultured wild-type and Slm2KO hippocampal neurons
with cycloheximide (CHX), an inhibitor of protein translation.
As NMD depends on active translation, transcripts that are sub-
ject to NMD are stabilized upon translational arrest (Carter et al.,
1995). Slm1 transcript levels increased threefold uponCHX treat-
ment of wild-type neurons. (Fig. 4A; one-wayANOVAwith Bon-
ferroni post hoc test). Importantly, in Slm2KO cultures, Slm1
transcript levels were not further increased after CHX treatment
(Fig. 4A; one-way ANOVA with Bonferroni post hoc test, not
significant, p	 0.05).
In the same experiment, CHX treatment appears to slightly
elevate Slm2 transcripts in wild-type and Slm2KO neurons (Fig.
4A), although this trend did not reach statistical significance.
These findings are consistent with NMD of Slm1 mRNA
through a process that requires Slm2.One possiblemechanism of
how SLM2 could target Slm1 mRNA for NMD would be the
incorporation of alternative exon sequences through regulated
alternative splicing that attract exon junction complexes down-
stream of the stop codon in Slm1 transcripts. Through database
searches, we identified a previously uncharacterized potential
splice donor site in exon9 of Slm1, which would link two addi-
tional exons encoding the 3UTR (exons 10 and 11; Fig. 4B). We
hypothesized that an SLM2-driven alternative splicing event
might promote incorporation of these exons. To test this possi-
bility, we performed exon-spanning RT-PCRs for the presump-
tive exon 10 in the 3 UTR. We used primer sets binding
upstream and downstream of the potential internal splice donor
site flanking various exons of the Slm1 transcript (Fig. 4B). We
could confirm the novel transcript 2 variant linking exon 8 and
exon 10 (PCR products exons 8–10), representing the Slm1 vari-
ant containing a 3UTR intron, predicted to undergoNMD (Fig.
4D). In Slm2KO mice, we observed an increase in the alternative
transcript 1 variant containing exon 8–9b bothwithRT-PCR and
quantitative RT-PCR, confirming that the presence of SLM2 sup-
presses formation of this (stable) formof Slm1mRNA (Fig. 4C,D;
Dunnett’s multiple comparison test). Using primer pairs up-
stream of the internal splice donor site (exons 3 and 4, exons 8
and 9a), we further confirmed that the whole Slm1 transcript was
stabilized (Fig. 4C). Products containing exons 8–10 showed a
trend to decrease in Slm2KO cells (Fig. 4C). However, if these
mRNAs are indeed targeted for translation-dependent decay, this
is difficult to quantify. To further explore this possibility, we
performed CHX treatment of wild-type hippocampal neurons.
Exons 8–10-containing transcripts were significantly increased
in CHX-treated cells, consistent with the hypothesis that they are
targeted for NMD (Fig. 4E).
If Slm2 indeed targets Slm1mRNA for degradation, then Slm2
should be sufficient to suppress SLM1 expression when intro-
duced into SLM1-positive cell populations. AAV-mediated
SLM2 mis-expression in the DG of the mouse hippocampus in
vivo abolished SLM1 expression in dentate granule cells (Fig.
5A,B). SLM2was introduced into theDG at postnatal day 8 (P8),
and mis-expressing neurons were viable and developed appar-
ently normal axonal and dendritic processes when analyzed at
P40. However, their cell nuclei were devoid of SLM1 protein.
Thus, SLM2 is required and sufficient to regulate the cell type-
specific expression of SLM proteins in vivo.
Alternative splicing regulation in Slm1:Slm2DKO mice
SLM1 and SLM2 have partially overlapping targets; however,
they are expressed in largely nonoverlapping cell populations
(Stoss et al., 2004; Iijima et al., 2014). Thus, the upregulation of
SLM1 in Slm2KO neurons needs to be considered when interpret-
ing loss-of-function phenotypes. We set out to determine the
impact of Slm1 and Slm2 loss-of-function in Slm1:Slm2DKOmice.
Slm1:Slm2DKO mice were born at Mendelian frequencies and
Figure 5. A, Injection of AAV-viruses into the DG ofWT animals at postnatal day 8 (P8). Micewere analyzed at P40. Scale bar, 100m.B, Immunohistochemistry analysis ofWT animals injected
eitherwith pAAV-EGFP, as injection control, or pAAV-SLM2-Venus. Sectionswere stained for the nucleic acid stainHoechst, and antibodies against EGFP, SLM1, and SLM2. Scale bar, 50m.Bottom,
Higher-magnification views of fields from the overview panels. Color code for merge is GFP (green) and SLM1 (magenta).
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were viable. Successful ablation of SLM1 and SLM2 was verified
by immunohistochemistry (Fig. 6A) and Western blotting anal-
ysis (Fig. 6B). Slm1KO aswell as Slm2KOneurons fail to direct exon
skipping of Nrxn1-3 at AS4, which correlates with their regional
expression in the brain (Ehrmann et al., 2013, Iijima et al., 2014).
To explore how simultaneous loss of both RNA binding proteins
affects neuronal alternative splicing regulation, we examined the
Nrxn AS4 regulation in the Slm1KO, Slm2KO, and Slm1:Slm2DKO
mice. Analysis of cortical and hippocampal tissue revealed that
splicing patterns were altered for all threeNrxn genes. Expression
of AS4() forms was significantly reduced in Slm2KO and com-
pletely abolished in the Slm1:Slm2DKO. By contrast, the splicing
patterns in the Slm1KO cortex and hippocampus remained un-
changed (Fig. 6C,D). Quantitative RT-PCR revealed that overall
Nrxn1, Nrxn2, and Nrxn3 levels were unaltered in all three mu-
tants and confirmed a striking increase of AS4() inNrxn1–3 for
the Slm2KO and the Slm1:Slm2DKO (Fig. 6D; two-way ANOVA).
Notably, there was a significant loss ofNrxn AS4- splice isoforms
in Slm2KO hippocampus, despite the substantial upregulation of
SLM1 in SLM2-deficient cells. Thus, in vivo, SLM1 upregulation
cannot significantly compensate for loss of SLM2, at least with
respect to alternative splicing regulation of Nrxns at AS4.
Discussion
In mammals, regulated alternative splicing events are wide-
spread; however, the factors underlying the generation of neuro-
nal cell type-specific alternative patterns are poorly understood.
The ability of alternative splicing to generate mRNA isoforms
that are targeted for NMD extends the functional impact of alter-
native splicing regulation from the generation of multiple iso-
forms derived from a single gene to the spatial and temporal
control of transcript levels. In this study, we set out to uncover in
vivo functions of SLM2 in neurons and identified an unexpected
role in setting up the mutually exclusive expression of SLM1 and
SLM2 paralogs in neuronal cell types.
We observed that SLM2 itself is required and sufficient for the
mututally exclusive expression of SLM1 and SLM2 in genetically
and anatomically defined populations of neurons in the mouse
hippocampus. SLM2 promotes the incorporation of an alterna-
tive splice donor in the last coding exon of the Slm1 transcript.
Notably, transcripts with 3UTR introns have long been consid-
ered to be erroneous predictions as the resulting mRNAs would
be predicted to beNMD substrates. However, recent studies have
highlighted unexpected functions of some of these transcripts
(Bicknell et al., 2012). We identified one such transcript contain-
ing a 3UTR intron for Slm1. Our genetic gain- and loss-of-
function analysis in mice demonstrates that this mRNA is indeed
produced through SLM2-dependent alternative splicing and that
the resulting destabilization of the alternative Slm1 transcript
represents a fundamental mechanism underlying the neuronal
cell type-specific expression of SLM1 protein in vivo.
Previous studies performed largely in cell lines demonstrated
that splicing regulators are able to control their own expression
Figure6. A, Loss of SLM1andSLM2expression in the Slm1:Slm2DKOwasverifiedbySLM1andSLM2-specific immunostaining. Scale bar, 200m.B, Loss of SLM1andSLM2expression verification
in the Slm1KO, Slm2KO, and Slm1:Slm2DKO by Western blotting analysis. Two gels were loaded with equal amounts of sample for the individual genotypes; however, the tubulin control displayed
derived from the gel also probed for SLM1. C, Representative images of semiquantitative RT-PCR with Nrxn AS4 in cortex and hippocampus from WT, Slm1KO, Slm2 KO, and Slm1:Slm2DKO mice. D,
Quantitative RT-PCR forNrxn1,Nrxn2, andNrxn3AS4 variants in hippocampal tissue. TotalNrxn1,Nrxn2, andNrxn3 levels are unchanged in the Slm1KO (n 3 animals), Slm2 KO (n 4 animals), and
Slm1:Slm2DKO (n 3 animals). For Slm2KO and Slm1:Slm2DKO, significant upregulation could be detected for Nrxn1, Nrxn2, and Nrxn3 AS4() and corresponding downregulation of Nrxn1, Nrxn2,
and Nrxn3 AS4(), respectively. In hippocampus, the Slm1KO did not display any changes for all three Nrxn genes at AS4 compared with WT animals. ns, Not significant ( p	 0.05). **p 0.01.
***p 0.001.
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by producing splice isoforms of their own mRNA that are tar-
geted for NMD (Lareau et al., 2007; Ni et al., 2007). Further
studies identified cross-regulation between paralogs of alterna-
tive splicing regulators, such as PTBP1 (polypyrimidine-tract-
binding protein 1) and PTBP2 (Boutz et al., 2007; Spellman et al.,
2007), to shift the alternative splicing patterns from precursors to
postmitotic neurons during differentiation and maturation in
development. Our results identify a similar cross-repression
mechanism for SLM1 and SLM2 to generate a highly spatially
restricted pattern of SLM paralogs in specific neuronal popula-
tions. SAM68, SLM1, and SLM2 bind similar RNA sequencemo-
tifs (Galarneau and Richard, 2009) and appear to regulate some
common targets. However, these proteins also exhibit certain
isoform-specific properties, including differential regulation by
kinases and selective associationwith additional alternative splic-
ing factors, which results in differential splicing activities (Stoss et
al., 2004; Iijima et al., 2011, 2014). Thus, SAM68 requires activa-
tion through calcium/CaMK4 signaling to modify alternative
splice isoformchoices ofNrxns, whereas SLM1and SLM2 seem to
be constitutively active in a cell type-specific manner. In themid-
brain, where SLM1 is highly expressed, Nrxn alternative splicing
at AS4 is significantly altered in Slm1KOmice (Iijima et al., 2014).
By contrast, in the hippocampus where SLM1 protein levels are
lower, its deletion has little impact on Nrxn1, Nrxn2, and Nrxn3
AS4 regulation. Possible explanations of why neither SAM68 nor
SLM1 rescued the splicing phenotype observed in Slm2KO cells
include that these cells lack signaling-dependent activation or
cofactors for SAM68 or SLM1 function, respectively.
Our work uncovers a mechanism underlying the mutually
exclusive, cell type-specific expression pattern of STAR proteins
in the mammalian brain. Loss of Slm2 function results in the
production ofNrxn variants with altered affinity for their synap-
tic binding partners (Boucard et al., 2005; Chih et al., 2006; Bau-
douin and Scheiffele, 2010; Uemura et al., 2010). Further studies
will be needed to determine the impact of Slm2-dependent alter-
native splicing with regards to changes in synaptic connectivity.
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